Clinical therapeutic effects of trastuzumab in HER2-positive breast cancer patients A protocol for systematic review and meta-analysis

被引：0

作者：

Tong, Chuanming ^{[1
]}

Wang, Chuan ^{[1
]}

Yang, Kun ^{[1
]}

机构：

[1] Peoples Hosp Dongxihu Dist, Dept Gen Surg, Wuhan 430040, Hubei, Peoples R China

来源：

MEDICINE | 2021年 / 100卷 / 17期

关键词：

breast cancer; efficacy; HER2; safety; trastuzumab; HER2;

D O I：

10.1097/MD.0000000000025685

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Despite the developments in diagnosis and treatment of HER2-positive metastatic breast cancer, there is a high likelihood in the development of resistance to trastuzumab. In general, HER2-positive patients with deteriorated health face negative clinical outcomes. The present study is conducted to systematically explore the medicinal properties of trastuzumab in HER2-positive breast cancer patients. Methods: Randomized controlled trials investigating the clinical properties of including trastuzumab to treat HER2-positive breast cancer cases will be sourced by exploring these online-based databases: MEDLINE, BIOSIS, China National Knowledge Infrastructure (CNKI), Cochrane Library, EMBASE, Central Register of Controlled Trials, and WanFang. Two independent authors will screen the literature, gather data, and assess the quality of selected studies. The significance of the relationship between the medical properties of trastuzumab when incorporated to treat HER2-positive breast cancer cases will be evaluated according to the relative risk, mean differences or standardized mean differences, and 95% confidence interval. Results: The outcomes from this review shall be issued in a journal that will be reviewed by peers. Conclusion: The conclusions presented in this review will serve as a reference for clinical practitioners and scholars to determine whether trastuzumab is an effective and safety intervention for treating HER2-positive breast cancer patients. Ethics and dissemination: Since this study is a systematic review of published studies, an ethical approval is not needed.

引用

页数：4

共 18 条

[1] OPERATING CHARACTERISTICS OF A BANK CORRELATION TEST FOR PUBLICATION BIAS [J].

BEGG, CB ;

MAZUMDAR, M .

BIOMETRICS, 1994, 50 (04) :1088-1101

[2] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

[3] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].

Cardoso, F. ;

Senkus, E. ;

Costa, A. ;

Papadopoulos, E. ;

Aapro, M. ;

Andre, F. ;

Harbeck, N. ;

Aguilar Lopez, B. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Boers-Doers, C. B. ;

Cardoso, M. J. ;

Carey, L. A. ;

Cortes, J. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. S. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Johnston, S. R. D. ;

Kaufmann, B. ;

Koppikar, S. ;

Krop, I. E. ;

Mayer, M. ;

Nakigudde, G. ;

Offersen, B. V. ;

Ohno, S. ;

Pagani, O. ;

Paluch-Shimon, S. ;

Penault-Llorca, F. ;

Prat, A. ;

Rugo, H. S. ;

Sledge, G. W. ;

Spence, D. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Xu, B. ;

Norton, L. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657

[4] Meta-analysis in clinical trials revisited [J].

DerSimonian, Rebecca ;

Laird, Nan .

CONTEMPORARY CLINICAL TRIALS, 2015, 45 :139-145

[5] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[6] High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller [J].

Gonzalez-Angulo, Ana M. ;

Litton, Jennifer K. ;

Broglio, Kristine R. ;

Meric-Bernstam, Funda ;

Rakkhit, Ronjay ;

Cardoso, Fatima ;

Peintinger, Florentia ;

Hanrahan, Emer O. ;

Sahin, Aysegul ;

Guray, Merih ;

Larsimont, Denis ;

Feoli, Francesco ;

Stranzl, Heidi ;

Buchholz, Thomas A. ;

Valero, Vicente ;

Theriault, Richard ;

Piccart-Gebhart, Martine ;

Ravdin, Peter M. ;

Berry, Donald A. ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5700-5706

[7] Quantifying heterogeneity in a meta-analysis [J].

Higgins, JPT ;

Thompson, SG .

STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558

[8] The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J].

Higgins, Julian P. T. ;

Altman, Douglas G. ;

Gotzsche, Peter C. ;

Jueni, Peter ;

Moher, David ;

Oxman, Andrew D. ;

Savovic, Jelena ;

Schulz, Kenneth F. ;

Weeks, Laura ;

Sterne, Jonathan A. C. .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 343

[9] US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status [J].

Howlader, Nadia ;

Altekruse, Sean F. ;

Li, Christopher I. ;

Chen, Vivien W. ;

Clarke, Christina A. ;

Ries, Lynn A. G. ;

Cronin, Kathleen A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05)

[10]

MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719

← 1 2 →